Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2021.1941938 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The evolving treatment landscape of multiple myeloma in Portugal: A nation-wide retrospective cohort study of real-world clinical practice.
EJHaem
December 2024
Johnson & Johnson Innovative Medicine Lisbon Portugal.
Objectives: To characterize variations in real-world treatment patterns in multiple myeloma (MM) in Portugal over a 5-year period.
Methods: A retrospective cohort multicenter study using secondary data of national hospital drug consumption database from 11 Portuguese public hospitals between 2017 and 2022.
Results: Number of MM-treated patients increased 53% over 5 years (from 825 to 1266 patients).
Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center.
Hematology
December 2024
Beijing Chaoyang Hospital, Capital Medical University, Beijing, People's Republic of China.
Objective: To analyze the efficacy of daratumumab-based regimen in newly diagnosed multiple myeloma(NDMM) patients with paraskeletal plasmacytomas (PPs).
Methods: The medical data of 28 NDMM patients with PPs were retrospectively analyzed. The daratumumab-based regimen was divided into group A, and the daratumumab-free regimen was divided into group B.
Efficacy of Daratumumab-Based Regimens for Extramedullary Pulmonary Plasmacytoma: A Case Report.
Cancer Rep (Hoboken)
November 2024
Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
Introduction: Multiple myeloma (MM) with pulmonary extramedullary disease is rare and usually associated with poor prognosis, and no data on daratumumab-based regimens have been reported yet.
Case Presentation: Here, a 64-year-old man with pulmonary plasmacytoma received daratumumab-based regimens and has achieved a very good partial response with lung mass disappearance and overall survival of 16 months. He did not receive autologous stem cell transplantation because of several comorbidities, such as severe drug-induced neuropathy and JAK2-mutated myeloproliferative neoplasm with marked splenomegaly.
Open-Label Phase 1/2 Study of Daratumumab-Based Desensitization Before Kidney Transplantation.
Kidney Int Rep
November 2024
Universite Paris Est Creteil, INSERM IMRB U955, Créteil, France.
Article Synopsis
- The study assesses the safety and efficacy of the anti-CD38 monoclonal antibody daratumumab for kidney transplant candidates with high panel reactive antibodies.
- In the trial, 23 patients were involved across two phases, with notable mild infusion-related adverse events but no serious complications.
- Results showed significant, temporary reductions in anti-HLA antibodies at 3 months, but most immune markers returned to baseline levels after 12 months, indicating less than 40% of patients had a lasting positive response.
Predictors and Profile of Severe Infectious Complications in Multiple Myeloma Patients Treated with Daratumumab-Based Regimens: A Machine Learning Model for Pneumonia Risk.
Cancers (Basel)
November 2024
Department of Hematooncology, Provincial Multi-Specialized Oncology and Trauma Center, 93-513 Lodz, Poland.
Background: Daratumumab (Dara) is the first monoclonal antibody introduced into clinical practice to treat multiple myeloma (MM). It currently forms the backbone of therapy regimens in both newly diagnosed (ND) and relapsed/refractory (RR) patients. However, previous reports indicated an increased risk of infectious complications (ICs) during Dara-based treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!